X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Piramal Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs PIRAMAL ENTERPRISES - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

PIRAMAL ENTERPRISES 
   Change

Piramal Enterprises has a presence in custom manufacturing, critical care OTC and financial services. To give a boost to its custom manufacturing operations, the company had acquired Avecia Pharmaceuticals, UK in 2005 and Pfizer's Morpeth facility in... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA PIRAMAL ENTERPRISES GLENMARK PHARMA/
PIRAMAL ENTERPRISES
 
P/E (TTM) x 17.1 32.3 52.9% View Chart
P/BV x 3.0 1.5 202.5% View Chart
Dividend Yield % 0.3 1.1 31.8%  

Financials

 GLENMARK PHARMA   PIRAMAL ENTERPRISES
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
PIRAMAL ENTERPRISES
Mar-18
GLENMARK PHARMA/
PIRAMAL ENTERPRISES
5-Yr Chart
Click to enlarge
High Rs9303,083 30.2%   
Low Rs5171,902 27.2%   
Sales per share (Unadj.) Rs322.6589.7 54.7%  
Earnings per share (Unadj.) Rs28.5284.0 10.0%  
Cash flow per share (Unadj.) Rs39.2310.5 12.6%  
Dividends per share (Unadj.) Rs2.0025.00 8.0%  
Dividend yield (eoy) %0.31.0 27.6%  
Book value per share (Unadj.) Rs183.01,467.0 12.5%  
Shares outstanding (eoy) m282.17180.27 156.5%   
Bonus/Rights/Conversions -IS-  
Price / Sales ratio x2.24.2 53.1%   
Avg P/E ratio x25.48.8 289.5%  
P/CF ratio (eoy) x18.58.0 230.1%  
Price / Book Value ratio x4.01.7 232.8%  
Dividend payout %7.08.8 79.8%   
Avg Mkt Cap Rs m204,206449,332 45.4%   
No. of employees `00013.76.8 200.4%   
Total wages/salary Rs m18,71819,881 94.2%   
Avg. sales/employee Rs Th6,636.815,535.6 42.7%   
Avg. wages/employee Rs Th1,364.72,905.4 47.0%   
Avg. net profit/employee Rs Th586.17,482.5 7.8%   
INCOME DATA
Net Sales Rs m91,031106,310 85.6%  
Other income Rs m9142,595 35.2%   
Total revenues Rs m91,945108,906 84.4%   
Gross profit Rs m16,15451,599 31.3%  
Depreciation Rs m3,0194,773 63.2%   
Interest Rs m2,85629,783 9.6%   
Profit before tax Rs m11,19319,638 57.0%   
Minority Interest Rs m02,801 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155-28,764 -11.0%   
Profit after tax Rs m8,03951,203 15.7%  
Gross profit margin %17.748.5 36.6%  
Effective tax rate %28.2-146.5 -19.2%   
Net profit margin %8.848.2 18.3%  
BALANCE SHEET DATA
Current assets Rs m69,887118,154 59.1%   
Current liabilities Rs m32,879462,260 7.1%   
Net working cap to sales %40.7-323.7 -12.6%  
Current ratio x2.10.3 831.6%  
Inventory Days Days8127 306.4%  
Debtors Days Days9347 200.9%  
Net fixed assets Rs m28,892113,727 25.4%   
Share capital Rs m282361 78.3%   
"Free" reserves Rs m51,353264,093 19.4%   
Net worth Rs m51,635264,454 19.5%   
Long term debt Rs m41,418242,206 17.1%   
Total assets Rs m125,954726,834 17.3%  
Interest coverage x4.91.7 296.5%   
Debt to equity ratio x0.80.9 87.6%  
Sales to assets ratio x0.70.1 494.1%   
Return on assets %8.611.1 77.6%  
Return on equity %15.619.4 80.4%  
Return on capital %15.110.3 146.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31715,110 240.4%   
Fx outflow Rs m9,7204,298 226.2%   
Net fx Rs m26,59810,813 246.0%   
CASH FLOW
From Operations Rs m16,481-159,666 -10.3%  
From Investments Rs m-10,133-17,677 57.3%  
From Financial Activity Rs m-4,685186,503 -2.5%  
Net Cashflow Rs m1,7709,364 18.9%  

Share Holding

Indian Promoters % 48.3 52.9 91.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 6.9 4.0 172.5%  
FIIs % 34.4 26.6 129.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 16.5 63.6%  
Shareholders   56,727 93,274 60.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   DIVIS LABORATORIES  WOCKHARDT  AUROBINDO PHARMA  PLETHICO PHARMA  FDC LTD.  

Compare GLENMARK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Hit Record High as Exit Polls Predict NDA Win; Sensex Ends 1,421 Points Higher(Closing)

Indian share markets witnessed huge buying interest today. The benchmark indices opened gap-up after Exit Polls for the Lok Sabha Elections 2019.

Related Views on News

NARAYANA HRUDAYALAYA LTD Surges by 5%; BSE HEALTHCARE Index Up 1.0% (Market Updates)

May 20, 2019 | Updated on May 20, 2019

NARAYANA HRUDAYALAYA LTD share price has surged by 5% and its current market price is Rs 199. The BSE HEALTHCARE is up by 1.0%. The top gainers in the BSE HEALTHCARE Index are NARAYANA HRUDAYALAYA LTD (up 5.2%) and PIRAMAL ENTERPRISES (up 7.1%). The top losers are FORTIS HEALTHCARE (down 0.2%) and ALEMBIC PHARMA (down 0.4%).

CAPLIN POINT Surges by 5%; BSE HEALTHCARE Index Up 0.8% (Market Updates)

May 20, 2019 | Updated on May 20, 2019

CAPLIN POINT share price has surged by 5% and its current market price is Rs 378. The BSE HEALTHCARE is up by 0.8%. The top gainers in the BSE HEALTHCARE Index are CAPLIN POINT (up 5.4%) and PIRAMAL ENTERPRISES (up 6.9%). The top losers are GLENMARK PHARMA and BLISS GVS PHARMA (down 0.1%).

ADVANCED ENZYME TECHNOLOGIES Surges by 10%; BSE HEALTHCARE Index Up 0.7% (Market Updates)

May 20, 2019 | Updated on May 20, 2019

ADVANCED ENZYME TECHNOLOGIES share price has surged by 10% and its current market price is Rs 185. The BSE HEALTHCARE is up by 0.7%. The top gainers in the BSE HEALTHCARE Index are ADVANCED ENZYME TECHNOLOGIES (up 9.8%) and PIRAMAL ENTERPRISES (up 6.0%). The top losers are SUN PHARMA ADV. RES. (down 0.2%) and ALEMBIC PHARMA (down 0.3%).

PIRAMAL ENTERPRISES Surges by 5%; BSE HEALTHCARE Index Up 0.9% (Market Updates)

May 20, 2019 | Updated on May 20, 2019

PIRAMAL ENTERPRISES share price has surged by 5% and its current market price is Rs 2,248. The BSE HEALTHCARE is up by 0.9%. The top gainers in the BSE HEALTHCARE Index is PIRAMAL ENTERPRISES (up 5.1%). The top losers are ALEMBIC PHARMA and SUN PHARMA ADV. RES. (down 0.3%).

PIRAMAL ENTERPRISES Announces Quarterly Results (4QFY19); Net Profit Down 91.4% (Quarterly Result Update)

Apr 30, 2019 | Updated on Apr 30, 2019

For the quarter ended March 2019, PIRAMAL ENTERPRISES has posted a net profit of Rs 3 bn (down 91.4% YoY). Sales on the other hand came in at Rs 37 bn (up 23.0% YoY). Read on for a complete analysis of PIRAMAL ENTERPRISES's quarterly results.

More Views on News

Most Popular

These Dividend Stocks Could Boost Your Returns Better Than You Can Imagine(Profit Hunter)

May 7, 2019

The art of dividend investing is a lot more than investing in companies with high dividend payouts or stocks with high dividend yields...

3 Indian Stocks Replicating Amazon's Successful Strategy(The 5 Minute Wrapup)

May 10, 2019

The one critical element that has made Amazon a force to reckon with...

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

A Simple Checklist for Picking Great Dividend Stocks(Profit Hunter)

May 9, 2019

A filtered, neat list of high-dividend stocks with all this dirty work already done for you.

A 10-Bagger in Just 6 Years! The Rebirth of India Will Create More Big Winners Like This(The 5 Minute Wrapup)

May 7, 2019

How a niche tech startup battled all odds to eventually become a 10 bagger.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


May 20, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS